Biovie is trading 6.83% higher at $1.72 on September 25, 2026, with no clearly reported company-specific catalyst identified for the move. - Recent coverage centers on September 15 Phase 2 ADDRESS-LC results and a September 23 investor webinar, rather than a new announcement on September 25. - The broader market is modestly higher, but provided index gains are below the threshold for attributing Biovie’s move to market-wide momentum. - Trading activity and volume details were unavailable.